Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

News Conference News ESC 2024

More Data Diminish Support for Cath Lab Fasting Rules: SCOFF

L.A. McKeown

September 10, 2024

News Conference News ESC 2024

Streamlined European AF Guidelines Emphasize ‘Whole’ Patient

Todd Neale

September 06, 2024

News Conference News ESC 2024

SENIOR-RITA Offers Rare Insights Into Best Care for Older NSTEMI Patients

Michael O'Riordan

September 02, 2024

News Conference News ESC 2024

MitraClip vs Surgery for Severe FMR? MATTERHORN Claims Noninferiority

Shelley Wood

September 01, 2024

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

News Conference News ESC 2024

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

Michael O'Riordan

September 01, 2024

Presentation ESC 2024

Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes: the FINE-HEART Pooled Analysis of Cardiovascular, Kidney, and Mortality Outcomes

Presenter: Muthiah Vaduganathan

September 01, 2024

News Conference News ESC 2024

Polypills Show Promise in Diverse Hypertensive Patient Groups

L.A. McKeown

August 31, 2024

News Conference News ESC 2024

Stop-or-Not: It’s OK to Tailor RAS Inhibitor Use Around Noncardiac Surgery

Todd Neale

August 30, 2024

Advertisement

More Data Diminish Support for Cath Lab Fasting Rules: SCOFF

Streamlined European AF Guidelines Emphasize ‘Whole’ Patient

SENIOR-RITA Offers Rare Insights Into Best Care for Older NSTEMI Patients

MitraClip vs Surgery for Severe FMR? MATTERHORN Claims Noninferiority

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes: the FINE-HEART Pooled Analysis of Cardiovascular, Kidney, and Mortality Outcomes

Polypills Show Promise in Diverse Hypertensive Patient Groups

Stop-or-Not: It’s OK to Tailor RAS Inhibitor Use Around Noncardiac Surgery

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content